Ahmed Saima, Ahmed Ejaz, Naqvi Rubina, Qureshi Sehar
Department of Nephrology, Sindh Institute of Urology and Transplantation, Karachi.
J Pak Med Assoc. 2012 Dec;62(12):1326-9.
To evaluate the prevalence and contributing factors causing post transplant erythrocytosis in renal transplant patients.
This retrospective study was conducted on live related renal transplant patients at SIUT. The records of all transplant recipients transplanted between April 2008 and December 2008 and who had at least 24 months follow up were studied. Patients in whom haematocrit exceeded 51% and those who received treatment for it were classified into post transplant erythrocytosis group.
Out of 200 renal transplant patients who had functioning graft at the time of analysis, 40 (20%) developed post transplant erythrocytosis (HCT > or = 51%) after a mean interval of 9.5 +/- 2.5 months. Patients with erythrocytosis were mostly males (95% in PTE group vs 73.75% in non PTE group), had a shorter period on dialysis before undergoing renal transplantation (9.28 months in PTE group vs 14.56 months in non PTE group) and had relatively better graft function at the onset of erythrocytosis as judged by serum creatinine (S. Creatinine of 1.06 +/- 0.29 mg/dl in PTE group vs 1.37 +/- 0.51 mg/dl in non PTE group). No thrombotic complications were observed. All patients with erythrocytosis were treated with enalapril (ACE inhibitors) and 28 out of 40 required phlebotomy in addition to ACE inhibitors. The mean HCT at the time of last follow up in treated patients was 48.61 +/- 1.85%.
Post transplant erythrocytosis generally occurs in male patients with good graft function, thrombotic complications are of rare occurrence and response to ACE inhibitors is good.
评估肾移植患者移植后红细胞增多症的患病率及相关影响因素。
本回顾性研究针对在卡拉奇大学医学科学研究所(SIUT)接受亲属活体肾移植的患者开展。研究了2008年4月至2008年12月期间接受移植且至少随访24个月的所有移植受者的记录。将血细胞比容超过51%的患者以及接受过相关治疗的患者归入移植后红细胞增多症组。
在分析时移植肾功能良好的200例肾移植患者中,40例(20%)在平均9.5±2.5个月的间隔期后发生了移植后红细胞增多症(血细胞比容≥51%)。红细胞增多症患者大多为男性(移植后红细胞增多症组为95%,非移植后红细胞增多症组为73.75%),肾移植前透析时间较短(移植后红细胞增多症组为9.28个月,非移植后红细胞增多症组为14.56个月),且根据血清肌酐判断,红细胞增多症发作时移植肾功能相对较好(移植后红细胞增多症组血清肌酐为1.06±0.29mg/dl,非移植后红细胞增多症组为1.37±0.51mg/dl)。未观察到血栓形成并发症。所有红细胞增多症患者均接受依那普利(一种血管紧张素转换酶抑制剂)治疗,40例中有28例除接受血管紧张素转换酶抑制剂治疗外还需要进行放血治疗。治疗患者末次随访时的平均血细胞比容为48.61±1.85%。
移植后红细胞增多症一般发生在移植肾功能良好的男性患者中,血栓形成并发症罕见,对血管紧张素转换酶抑制剂反应良好。